i2o: GLP-1 startup i2o looks to revive diabetes drug-eluting implant from Intarcia

i2o Therapeutics says it acquired the diabetes-treating assets of one-time medtech unicorn Intarcia Therapeutics. The Boston-based company acquired and integrated Intarcia's proprietary assets and made a big personnel move. With CEO Ravi Srinivasan moving onto other opportunities, i2o named Kurt Graves as chair, president and CEO. Graves previously served as executive chair of the i2o [...]The post GLP-1 startup i2o looks to revive diabetes drug-eluting implant from Intarcia appeared first on Drug Delivery Business.